Generating elastic, biodegradable polyurethane/poly(lactide-co-glycolide) fibrous sheets with controlled antibiotic release via two-stream electrospinning.
Damage control laparotomy is commonly applied to prevent compartment syndrome following trauma but is associated with new risks to the tissue, including infection. To address the need for biomaterials to improve abdominal laparotomy management, we fabricated an elastic, fibrous composite sheet with two distinct submicrometer fiber populations: biodegradable poly(ester urethane) urea (PEUU) and poly(lactide-co-glycolide) (PLGA), where the PLGA was loaded with the antibiotic tetracycline hydrochloride (PLGA-tet). A two-stream electrospinning setup was developed to create a uniform blend of PEUU and PLGA-tet fibers. Composite sheets were flexible with breaking strains exceeding 200%, tensile strengths of 5-7 MPa, and high suture retention capacity. The blending of PEUU fibers markedly reduced the shrinkage ratio observed for PLGA-tet sheets in buffer from 50% to 15%, while imparting elastomeric properties to the composites. Antibacterial activity was maintained for composite sheets following incubation in buffer for 7 days at 37 degrees C. In vivo studies demonstrated prevention of abscess formation in a contaminated rat abdominal wall model with the implanted material. These results demonstrate the benefits derivable from a two-stream electrospinning approach wherein mechanical and controlled-release properties are contributed by independent fiber populations and the applicability of this composite material to abdominal wall closure.
Hong
Yi
Y
McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, USA.
Fujimoto
Kazuro
K
Hashizume
Ryotaro
R
Guan
Jianjun
J
Stankus
John J
JJ
Tobita
Kimimasa
K
Wagner
William R
WR
D000005:Abdomen / Q000382:microbiology / Q000473:pathology / Q000601:surgery*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D004343:Drug Implants / Q000737:chemistry*; D004563:Electrochemistry / Q000379:methods*; D004926:Escherichia coli / Q000187:drug effects / Q000378:metabolism; D005260:Female; D019344:Lactic Acid / Q000737:chemistry*; D036103:Nanotechnology / Q000379:methods; D011091:Polyesters / Q000737:chemistry*; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry; D011140:Polyurethanes / Q000737:chemistry*; D011183:Postoperative Complications / Q000517:prevention & control; D051381:Rats; D011917:Rats, Inbred Lew; D017207:Rats, Sprague-Dawley; D013752:Tetracycline / Q000008:administration & dosage*; D000267:Tissue Adhesions / Q000209:etiology / Q000517:prevention & control*; D014520:Urethane / Q000737:chemistry*
D000900:Anti-Bacterial Agents; D004343:Drug Implants; D011091:Polyesters; D011108:Polymers; D011140:Polyurethanes; C401107:poly(ortho ester); D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D014520:Urethane; D013752:Tetracycline